DPX-0907 / BioVaxys - LARVOL DELTA

IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results (Businesswire) - “Maveropepimut-S - Q1 2021: Finalization of clinical protocol and collaboration agreement with partner for Phase 2B clinical trial in r/r DLBCL; Q2 2021: Translational and Biomarker analysis update for Ovarian cancer DeCidE1 trial; Q2 2021: Initiation of r/r DLBCL Phase 2B trial; H2 2021: Meeting with the FDA and final clinical design for a Phase 2B study in Advanced Recurrent Ovarian Cancer; H2 2021: Updated results for the basket trial. DPX-SurMAGE - H2 2021: Initiation of a Phase 1 clinical study in bladder cancer.”

Clinical protocol • FDA event • New P1 trial • New P2b trial • Bladder Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer